S. Wardell

发表

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report

S. Patel, P. Hwu, S. Woodman, 2015, Cancer Immunology Research.

Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma

Young Uk Kim, R. Amaria, S. Patel, 2018, Journal of immunotherapy.

Genetic and molecular characterization of uveal melanoma cell lines

S. Woodman, B. Bastian, C. Bernatchez, 2012, Pigment cell & melanoma research.

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

Dennie T. Frederick, J. Wargo, P. Hwu, 2012, Clinical Cancer Research.

Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Jeffrey E. Lee, V. Johnson, M. Ross, 2012, Clinical Cancer Research.

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome

Young Uk Kim, Jeffrey E. Lee, R. Beroukhim, 2018, Clinical Cancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

Esteban Flores, Cara Haymaker, Weiyi Peng, 2017, Front. Immunol..

Predictive Biomarkers and Personalized Medicine Speci fi c Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-In fi ltrating Lymphocytes in Metastatic Melanoma Patients

Jeffrey E. Lee, V. Johnson, M. Ross, 2012 .

Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.

A. Chopra, Amy N. Courtney, P. Nehete, 2007, Vaccine.

Abstract 2746: Preclinical activity and manufacturing feasibility of genetically modified PDCD-1 knockout (KO) tumor-infiltrating lymphocyte (TIL) cell therapy

R. Cubas, M. Jagasia, Jamie Blauvelt, 2022, Cancer Research.

Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma

Dennie T. Frederick, J. Wargo, P. Hwu, 2012, Clinical Cancer Research.

Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report

S. Patel, P. Hwu, S. Woodman, 2015, Cancer Immunology Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.